Company
LON:RENE
ReNeuron Group PLC has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. Through the generation of several unique and scalable exosome producer cell lines, its CustomEX ™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes.
298 stories · page 12 of 15
Following “favourable feedback” from the Food & Drug Administration, the watchdog specifically recommended the company apply for a Special Protocol Assessment (SPA) for the phase III study.
The FTSE 100 was subdued in early trade and after the weekend's horrors
Archive
A glance at the stories on the Proactive newswire today ..
Data shows that ExoPr0 can cross the blood brain barrier and can potentially target multiple diseases via local or systemic administration
Investments and investor services
Well, it's not a triple digit fall for the FTSE 100 on Thursday
A look at some of the biggest London-listed risers and fallers today
The grant will fund key process development activities relating to larger scale commercial manufacture of ReNeuron's cell therapy candidates.
Archive
A reverse takeover of Opera Investments is the method for the deal with the name of the company to be changed to Katoro Gold PLC to reflect the new business focus.
Exosome therapy is being explored by ReNeuron both as a potential new nanomedicine targeting cancer and as a delivery system for gene therapy treatments.
Telit Communications shares have fallen after announcing a fundraising while Diversified Gas & Oil has gained on acquisition news
London's top tier index rose 22 points to 7,270.88 at 2.38pm after a better-than-expected US non-farm payrolls report
Archive
A glance at some of the stories on the Proactive newswire today
A look at some of the hot stocks in early deals on Friday
The company said it is preparing to meet with US regulators on plans for a phase III trial of its treatment for victims of stroke, while it wants to expand its ophthalmology study
Friday was a bit of a wash-out, with the Footsie ending little changed after a rough week
Archive
Also featured: AFC, Ferrum Crescent, Galileo, Kibo, Lansdowne Oil, Metal Tiger, Netscientific, Powerhouse, REM, ReNeuron, Tern
The cell-based therapeutics group featured in the ‘Andrew Marr: My Brain and Me’ documentary last night
Archive
A glance at today's headlines on the Proactive newswire …
